With the introduction of the complement C5-inhibitor eculizumab, a new era was entered for
patients with atypical hemolytic uremic syndrome (aHUS). Eculizumab therapy very …

Introduction The introduction of eculizumab has improved the outcome in patients with
atypical hemolytic uremic syndrome (aHUS). The optimal treatment strategy is debated …

Atypical hemolytic uremic syndrome (aHUS) is caused by alternative complement pathway
dysregulation, leading to systemic thrombotic microangiopathy (TMA) and severe end-organ …

The optimal duration of eculizumab treatment in patients with atypical hemolytic uremic
syndrome (aHUS) remains poorly defined. We conducted a prospective national multicenter …

Atypical hemolytic uremic syndrome (aHUS) is a life-threatening thrombotic
microangiopathy, and as many as 70% of patients with aHUS have mutations in the genes …

Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy associated
with defective regulation of the alternative complement pathway. The prognosis for patients …

Background There are limited long-term outcome data in eculizumab-treated patients with
atypical hemolytic uremic syndrome (aHUS). We report final results from the largest …

Background Atypical haemolytic uremic syndrome (aHUS) is a rare but severe form of
thrombotic microangiopathy as a consequence of complement dysregulation. aHUS has a …

Background Atypical hemolytic uremic syndrome (aHUS) is a rare genetic life-threatening
disease of chronic uncontrolled complement activation leading to thrombotic …

Background Atypical hemolytic uremic syndrome (aHUS) is a devastating form of renal
thrombotic microangiopathy. Despite plasma exchange, the standard treatment of aHUS for …